Opinion
Video
Marcia Brose, MD, examines data from the COSMIC-311 study, emphasizing the importance of promptly initiating second-line therapy for patients who have progressed on first-line treatments.
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise